{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:56:11Z","timestamp":1762505771991,"version":"build-2065373602"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brainanddevelopment.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.braindev.2011.04.010","type":"journal-article","created":{"date-parts":[[2011,5,13]],"date-time":"2011-05-13T06:08:26Z","timestamp":1305266906000},"page":"213-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Valproic acid increases SMN2 expression and modulates SF2\/ASF and hnRNPA1 expression in SMA fibroblast cell lines"],"prefix":"10.1016","volume":"34","author":[{"given":"Indra Sari Kusuma","family":"Harahap","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lai Poh","family":"San","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Gunadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dian Kesuma Pramudya","family":"Nurputra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surini","family":"Yusoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoto","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myeong Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisahide","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2011.04.010_b0005","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time LightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldk\u00f6tter","year":"2002","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.braindev.2011.04.010_b0010","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0960-8966(99)00016-4","article-title":"59th ENMC International Workshop: Spinal Muscular Atrophies: recent progress and revised diagnostic criteria 17\u201319 April 1998, Soestduinen, The Netherlands","volume":"9","author":"Zerres","year":"1999","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.braindev.2011.04.010_b0015","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/344540a0","article-title":"Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2\u201313.3","volume":"344","author":"Brzustowicz","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.braindev.2011.04.010_b0020","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/345823a0","article-title":"Genetic homogeneity between acute and chronic forms of spinal muscular atrophy","volume":"345","author":"Gilliam","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.braindev.2011.04.010_b0025","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/344767a0","article-title":"Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q","volume":"344","author":"Melki","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.braindev.2011.04.010_b0030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.braindev.2011.04.010_b0035","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ng0797-265","article-title":"Correlation between severity and SMN protein level in spinal muscular atrophy","volume":"16","author":"Lefebvre","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.braindev.2011.04.010_b0040","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9","article-title":"An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA)","volume":"15","author":"Wirth","year":"2000","journal-title":"Hum Mutat"},{"key":"10.1016\/j.braindev.2011.04.010_b0045","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/ng1195-335","article-title":"A frame-shift deletion in the survival motor neuron gene in Spanish spinal muscular atrophy patients","volume":"11","author":"Bussaglia","year":"1995","journal-title":"Nat Genet"},{"key":"10.1016\/j.braindev.2011.04.010_b0050","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s100480050021","article-title":"Molecular diagnosis of non-deletion SMA patients using quantitative PCR of SMN exon 7","volume":"1","author":"Rochette","year":"1997","journal-title":"Neurogenetics"},{"key":"10.1016\/j.braindev.2011.04.010_b0055","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1086\/302160","article-title":"Intragenic telSMN mutations: frequency, distribution, evidence of a founder effect, and modification of the spinal muscular atrophy phenotype by cenSMN copy number","volume":"63","author":"Parsons","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.braindev.2011.04.010_b0060","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00415-002-0811-4","article-title":"Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy: three SMN2 copies fail to rescue some patients from the disease severity","volume":"249","author":"Harada","year":"2002","journal-title":"J Neurol"},{"key":"10.1016\/j.braindev.2011.04.010_b0065","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/hmg\/9.3.333","article-title":"The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn-\/- mice and results in a mouse with spinal muscular atrophy","volume":"9","author":"Monani","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.braindev.2011.04.010_b0070","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","article-title":"A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2","volume":"8","author":"Monani","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.braindev.2011.04.010_b0075","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.braindev.2011.04.010_b0080","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/nsb887","article-title":"Correction of disease-associated exon skipping by synthetic exon-specific activators","volume":"10","author":"Cartegni","year":"2003","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.braindev.2011.04.010_b0085","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/ng854","article-title":"Disruption of an SF2\/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1","volume":"30","author":"Cartegni","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.braindev.2011.04.010_b0090","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/hmg\/9.2.259","article-title":"An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN","volume":"9","author":"Lorson","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.braindev.2011.04.010_b0095","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/ng1207","article-title":"A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy","volume":"34","author":"Kashima","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.braindev.2011.04.010_b0100","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1093\/hmg\/10.24.2841","article-title":"Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients","volume":"10","author":"Andreassi","year":"2001","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.braindev.2011.04.010_b0105","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/sj.gt.3301550","article-title":"An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA","volume":"8","author":"Zhang","year":"2001","journal-title":"Gene Ther"},{"key":"10.1016\/j.braindev.2011.04.010_b0110","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ana.20548","article-title":"Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells","volume":"58","author":"Grzeschik","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.braindev.2011.04.010_b0115","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/WNL.59.4.609","article-title":"Pilot trial of albuterol in spinal muscular atrophy","volume":"59","author":"Kinali","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2011.04.010_b0120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/jmg.2007.051177","article-title":"Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells","volume":"45","author":"Angelozzi","year":"2008","journal-title":"J Med Genet"},{"key":"10.1016\/j.braindev.2011.04.010_b0125","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.nmd.2008.05.004","article-title":"Daily salbutamol in young patients with SMA type II","volume":"18","author":"Pane","year":"2008","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.braindev.2011.04.010_b0130","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1073\/pnas.0633863100","article-title":"Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts","volume":"100","author":"Skordis","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.braindev.2011.04.010_b0135","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev"},{"key":"10.1016\/j.braindev.2011.04.010_b0140","doi-asserted-by":"crossref","first-page":"7633","DOI":"10.1523\/JNEUROSCI.0950-09.2009","article-title":"Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy","volume":"29","author":"Williams","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.braindev.2011.04.010_b0145","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.braindev.2011.04.010_b0150","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000208","article-title":"Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy","volume":"1","author":"Hastings","year":"2009","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.braindev.2011.04.010_b0155","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/BF03401830","article-title":"Interferons and IRF-1 induce expression of the survival motor neuron (SMN) genes","volume":"6","author":"Baron-Delage","year":"2000","journal-title":"Mol Med"},{"key":"10.1016\/j.braindev.2011.04.010_b0160","doi-asserted-by":"crossref","first-page":"9808","DOI":"10.1073\/pnas.171105098","article-title":"Treatment of spinal muscular atrophy by sodium butyrate","volume":"98","author":"Chang","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.braindev.2011.04.010_b0165","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/hmg\/ddg256","article-title":"Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy","volume":"12","author":"Brichta","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.braindev.2011.04.010_b0170","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ana.10743","article-title":"Valproic acid increases SMN levels in spinal muscular atrophy patient cells","volume":"54","author":"Sumner","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.braindev.2011.04.010_b0175","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.ejhg.5201320","article-title":"Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients","volume":"13","author":"Brahe","year":"2005","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.braindev.2011.04.010_b0180","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00439-006-0186-1","article-title":"The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA\/protein levels in spinal muscular atrophy cells","volume":"120","author":"Riessland","year":"2006","journal-title":"Hum Genet"},{"key":"10.1016\/j.braindev.2011.04.010_b0185","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1471-4159.2006.03868.x","article-title":"In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy","volume":"98","author":"Hahnen","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.braindev.2011.04.010_b0190","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1172\/JCI29562","article-title":"Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy","volume":"117","author":"Avila","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.braindev.2011.04.010_b0195","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1093\/hmg\/ddp313","article-title":"LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate","volume":"18","author":"Garbes","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.braindev.2011.04.010_b0200","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ana.20836","article-title":"In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate","volume":"59","author":"Brichta","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.braindev.2011.04.010_b0205","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1111\/j.1468-1331.2007.01992.x","article-title":"Valproic acid treatment in six patients with spinal muscular atrophy","volume":"14","author":"Tsai","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.braindev.2011.04.010_b0210","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.braindev.2011.04.010_b0215","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1128\/MCB.01262-08","article-title":"Regulation of SMN protein stability","volume":"29","author":"Burnett","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.braindev.2011.04.010_b0220","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"G\u00f6ttlicher","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/j.braindev.2011.04.010_b0225","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.braindev.2011.04.010_b0230","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/sj.ejhg.5201102","article-title":"Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy","volume":"12","author":"Andreassi","year":"2004","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.braindev.2011.04.010_b0235","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0920-1211(91)90028-E","article-title":"Comparison of valproate concentrations in human plasma, CSF and brain tissue after administration of different formulations of valproate or valpromide","volume":"9","author":"Wieser","year":"1991","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.braindev.2011.04.010_b0240","doi-asserted-by":"crossref","first-page":"9618","DOI":"10.1073\/pnas.160181697","article-title":"Htra2-\u03b21 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2)","volume":"97","author":"Hofmann","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.braindev.2011.04.010_b0245","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1093\/hmg\/11.17.2037","article-title":"HnRNP-G promotes exon 7 inclusion of survival motor neuron (SMN) via direct interaction with Htra2-\u03b21","volume":"11","author":"Hofmann","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.braindev.2011.04.010_b0250","doi-asserted-by":"crossref","first-page":"7284","DOI":"10.1128\/MCB.00476-07","article-title":"Histone deacetylase inhibitors reduce steroidogenesis through SCF-mediated ubiquitination and degradation of steroidogenic factor 1 (NR5A1)","volume":"27","author":"Chen","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.braindev.2011.04.010_b0255","doi-asserted-by":"crossref","first-page":"29745","DOI":"10.1074\/jbc.M203633200","article-title":"Distinct sets of adjacent heterogeneous nuclear ribonucleoprotein (hnRNP) A1\/A2 binding sites control 5\u2019 splice site selection in the hnRNP A1 mRNA precursor","volume":"277","author":"Hutchison","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.braindev.2011.04.010_b0260","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1212\/01.wnl.0000231139.26253.d0","article-title":"Valproate may improve strength and function in patients with type III\/IV spinal muscle atrophy","volume":"67","author":"Weihl","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2011.04.010_b0265","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1123\/jsr.17.2.160","article-title":"Hand-held dynamometry: reliability of lower extremity muscle testing in healthy, physically active, young adults","volume":"17","author":"Kelln","year":"2008","journal-title":"J Sport Rehabil"},{"key":"10.1016\/j.braindev.2011.04.010_b0270","doi-asserted-by":"crossref","first-page":"e5268","DOI":"10.1371\/journal.pone.0005268","article-title":"Phase II open label study of valproic acid in spinal muscular atrophy","volume":"4","author":"Swoboda","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.braindev.2011.04.010_b0275","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.nbd.2009.08.014","article-title":"Valproic acid blocks excitability in SMA type I mouse motor neurons","volume":"36","author":"Rak","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.braindev.2011.04.010_b0280","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF00228395","article-title":"Valproate and sodium currents in cultured hippocampal neurons","volume":"93","author":"Van den Berg","year":"1993","journal-title":"Exp Brain Res"},{"key":"10.1016\/j.braindev.2011.04.010_b0285","doi-asserted-by":"crossref","first-page":"e12140","DOI":"10.1371\/journal.pone.0012140","article-title":"S.M.A.C.A.R.N.I.-V.A.L. trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy","volume":"5","author":"Swoboda","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.braindev.2011.04.010_b0290","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1527-3458.2003.tb00249.x","article-title":"Valproate : past, present and future","volume":"9","author":"Johannessen","year":"2003","journal-title":"CNS Drug Reviews"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760411000994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760411000994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:46:56Z","timestamp":1759952816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760411000994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0387760411000994"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2011.04.010","relation":{},"ISSN":["0387-7604"],"issn-type":[{"type":"print","value":"0387-7604"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valproic acid increases SMN2 expression and modulates SF2\/ASF and hnRNPA1 expression in SMA fibroblast cell lines","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2011.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}